Companies › Gradalis
1 active drug program in 8 registered trials: 3 Phase 2, 2 Phase 4, 2 Phase 3, 1 Phase 1; Neurology, Immunology, Oncology, Other; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Modafinil Dopamine transporter inhibitor | SLC6A3 | Phase 2 | Ovarian Cancer; Sleep Deprivation; Attention - no Condition is Being Assessed - Healthy Adults; Cognition … | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06592352 | Modafinil | Phase 2 | Multiple Sclerosis | Neurology | Jun 2026 |
| NCT07830056 | Modafinil | Phase 4 | Sleep Deprivation | Other | Dec 2026 |
| NCT06041048 | Modafinil | Phase 4 | Attention - no Condition is Being Assessed - Healthy Adults | Other | Dec 2026 |
| NCT07582458 | Modafinil | Phase 2 | Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) | Immunology | Feb 2027 |
| NCT05333250 | Modafinil | Phase 1 | Cancer-related Cognitive Difficulties | Oncology | Oct 2027 |
| NCT02346747 | Modafinil | Phase 2 | Ovarian Cancer | Oncology | Dec 2028 |
| NCT07231497 | Modafinil | Phase 3 | Cognition | Other | Apr 2030 |
| NCT07263022 | Modafinil | Phase 3 | Psychosis | Psychiatry | Apr 2030 |
Shanton Pharma Pte. ArthroBiologix Forte Biosciences Newish Technology (Beijing) VivaTech International
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.